Dutta Abhijit, Manna Arijit, Ghosh Shubhamoy, Mundle Malay, Saha Madhabananda, Gourav Kumar, Maiti Sukhdeb, Chattopadhyay Bhargab
International Cooperation Section, Ministry of Ayush (Government of India), New Delhi, India.
State Homoeopathic Dispensary, District Hospital, Darjeeling, India.
Complement Med Res. 2024;31(2):140-148. doi: 10.1159/000536395. Epub 2024 Jan 29.
Homeopathic medicines have been used for decades in the prevention and treatment of infectious diseases. However, the preventive efficacy of specific homeopathic medicines in COVID-19 is not well characterized. This study aimed to evaluate the comparative efficacy of prespecified homeopathic medicines in preventing COVID-19.
A community-based, double-blind, randomized, placebo-controlled trial was conducted on 4,034 participants residing in Ward No. 27 of the Howrah Municipal Corporation in India. Participants were randomized to receive one of three prespecified homeopathic medicines [Influenzinum 30C, Arsenicum album 30C, Anas barbariae hepatis et cordis extractum 200K (Oscillococcinum®)], or placebo. The outcomes were the incidence of laboratory-confirmed and suspected cases of COVID-19 during a follow-up period of 1 month.
During the follow-up period, a total of 13 new laboratory-confirmed COVID-19 cases were reported in the study population. Among these, 5 cases in Influenzinum group, 2 cases in Arsenicum album group, 1 case in Oscillococcinum® group, and 5 cases in Placebo group were reported. On the other hand, number of suspected COVID-19 cases was significantly less in all the three homeopathic medicine groups compared to placebo. The least number of suspected cases reported in the Oscillococcinum® group (aOR: 0.058; 95% confidence interval [CI]: 0.029, 0.114), followed by the Arsenicum album (aOR: 0.337; 95% CI: 0.238, 0.475) and Influenzinum (aOR: 0.539; 95% CI: 0.401, 0.726) groups.
Prespecified homeopathic medicines, particularly Oscillococcinum® and Arsenicum album 30C, may have a role in preventing COVID-19, especially in reducing the incidence of suspected or COVID-19-like respiratory illnesses. However, the result failed to demonstrate a statistically significant difference in the occurrence of confirmed cases of COVID-19 between the study groups. Further research is needed to evaluate the efficacy of these medicines in different populations and settings.
顺势疗法药物已被用于预防和治疗传染病数十年。然而，特定顺势疗法药物在新冠疫情中的预防效果尚未得到充分明确。本研究旨在评估预先指定的顺势疗法药物预防新冠的相对疗效。
在印度豪拉市政公司第27区居住的4034名参与者中开展了一项基于社区的双盲随机安慰剂对照试验。参与者被随机分配接受三种预先指定的顺势疗法药物之一[流感病毒30C、白砷30C、鸭肝和心脏提取物200K（奥司他韦）]或安慰剂。观察指标为1个月随访期内实验室确诊和疑似新冠病例的发生率。
在随访期间，研究人群中共报告了13例新的实验室确诊新冠病例。其中，流感病毒组5例，白砷组2例，奥司他韦组1例，安慰剂组5例。另一方面，与安慰剂组相比，所有三个顺势疗法药物组的疑似新冠病例数均显著减少。奥司他韦组报告的疑似病例数最少（调整后比值比：0.058；95%置信区间[CI]：0.029，0.114），其次是白砷组（调整后比值比：0.337；95%CI：0.238，0.475）和流感病毒组（调整后比值比：0.539；95%CI：0.401，0.726）。
预先指定的顺势疗法药物，尤其是奥司他韦和白砷30C，可能在预防新冠方面发挥作用，特别是在降低疑似或新冠样呼吸道疾病的发生率方面。然而，结果未能证明研究组之间新冠确诊病例的发生存在统计学显著差异。需要进一步研究以评估这些药物在不同人群和环境中的疗效。
<标题>引言</标题>顺势疗法药物已被用于预防和治疗传染病数十年。然而，特定顺势疗法药物预防新冠的疗效尚未得到充分研究。本研究旨在评估特定顺势疗法药物预防新冠的相对疗效。<标题>方法</标题>这是一项基于社区的双盲随机安慰剂对照研究，有4034名参与者，他们生活在印度豪拉市政公司第27区。参与者被随机分配接受三种预先指定的顺势疗法药物之一[流感病毒30C、白砷30C、鸭肝和心脏提取物200K（奥司他韦）]或安慰剂。观察指标为1个月随访期内实验室确诊和疑似新冠病例的发生率。<标题>结果</标题>在随访期间，研究人群中共报告了13例新的实验室确诊新冠病例，其中流感病毒组5例，白砷组2例，奥司他韦组1例，安慰剂组5例。相比之下，所有三个顺势疗法药物组的疑似新冠病例数均显著低于安慰剂组。奥司他韦组报告的疑似病例数最少（调整后比值比：0.058；95%置信区间：0.029，0.114），其次是白砷组（调整后比值比：0.337；95%置信区间：0.238，0.475）和流感病毒组（调整后比值比：0.539；95%置信区间：0.401，0.726）。<标题>结论</标题>特定顺势疗法药物，尤其是奥司他韦和白砷30C，可能在预防新冠方面发挥作用，特别是在降低疑似或新冠样呼吸道疾病的发生率方面。然而，研究组之间新冠确诊病例的发生情况没有统计学显著差异。需要进一步研究以评估这些药物在不同人群和环境中的疗效。
